Lorlatinib 25mg - Lucilorla

What it treats:

Lung Cancer

ALK-Positive Metastatic NSCLC: Lorlatinib is approved for adults with metastatic NSCLC that is anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test. It is typically used in patients who have progressed on prior ALK inhibitors, such as crizotinib, alectinib, or ceritinib, due to its ability to target resistant ALK mutations and penetrate the blood-brain barrier to address brain metastases.

Lorlatinib is a third-generation ALK/ROS1 tyrosine kinase inhibitor, designed to overcome resistance to earlier ALK inhibitors. Its use requires confirmation of ALK-positive status through genetic testing, and treatment should be overseen by a healthcare provider due to potential side effects, including central nervous system effects and hyperlipidemia.